{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T11:17:22Z","timestamp":1649071042433},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s11899-007-0029-8","type":"journal-article","created":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T17:40:20Z","timestamp":1191260420000},"page":"213-218","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab maintenance therapy in follicular lymphoma"],"prefix":"10.1007","volume":"2","author":[{"given":"Roswitha","family":"Forstpointner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,2]]},"reference":[{"key":"29_CR1","first-page":"75","volume":"20","author":"S.J. Horning","year":"1993","unstructured":"Horning SJ: Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas. Semin Oncol 1993, 20:75\u201388.","journal-title":"Semin Oncol"},{"key":"29_CR2","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P. McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"29_CR3","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"J.D. Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris HA 3rd, et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002, 20:4261\u20134267.","journal-title":"J Clin Oncol"},{"key":"29_CR4","doi-asserted-by":"crossref","unstructured":"Colombat P, Brousse N, Morschhauser F, Franchi-Rezgui P: Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F\/Up) of 7 years [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 486.","DOI":"10.1182\/blood.V108.11.486.486"},{"key":"29_CR5","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M. Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004, 103:4416\u20134423.","journal-title":"Blood"},{"key":"29_CR6","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R. Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064\u20133071.","journal-title":"Blood"},{"key":"29_CR7","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W. Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725\u20133732.","journal-title":"Blood"},{"key":"29_CR8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R. Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417\u20131423.","journal-title":"Blood"},{"key":"29_CR9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M. Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, et al.: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007, 25:1986\u20131992.","journal-title":"J Clin Oncol"},{"key":"29_CR10","first-page":"424s","volume":"24","author":"C. Foussard","year":"2006","unstructured":"Foussard C, Mounier N, Van Hoof A, et al.: Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients (pts) [abstract]. Proc Am Soc Clin Oncol 2006, 24:424s (Abstract 7508).","journal-title":"Proc Am Soc Clin Oncol"},{"key":"29_CR11","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"M.H. Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, et al.: Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295\u20133301.","journal-title":"Blood"},{"key":"29_CR12","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"T.A. Davis","year":"2000","unstructured":"Davis TA, Grillo-Lopez AJ, White CA, et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135\u20133143.","journal-title":"J Clin Oncol"},{"key":"29_CR13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"N.L. Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-Lopez AJ, White CA, et al.: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 1998, 9:995\u20131001.","journal-title":"Ann Oncol"},{"key":"29_CR14","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"J.D. Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, et al.: Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1088\u20131095.","journal-title":"J Clin Oncol"},{"key":"29_CR15","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","volume":"23","author":"L.N. Gordan","year":"2005","unstructured":"Gordan LN, Grow WB, Pusateri A, et al.: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005, 23:1096\u20131102.","journal-title":"J Clin Oncol"},{"key":"29_CR16","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"M. Ghielmini","year":"2005","unstructured":"Ghielmini M, Rufibach K, Salles G, et al.: Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005, 16:1675\u20131682.","journal-title":"Ann Oncol"},{"key":"29_CR17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"L.D. Piro","year":"1999","unstructured":"Piro LD, White CA, Grillo-Lopez AJ, et al.: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 1999, 10:655\u2013661.","journal-title":"Ann Oncol"},{"key":"29_CR18","doi-asserted-by":"crossref","unstructured":"Hochster H, Weller E, Gascoyne RD, et al.: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 349.","DOI":"10.1182\/blood.V106.11.349.349"},{"key":"29_CR19","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R. Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al.: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003\u20134008.","journal-title":"Blood"},{"key":"29_CR20","doi-asserted-by":"crossref","unstructured":"Dreyling M, Forstpointner R, Boeck H-P, et al.: Combined immuno-chemotherapy followed by rituximab maintenance is an effective salvage treatment after prior rituximab containing therapy: results of a GLSG-subgroup analysis in patients with relapsed indolent lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2769.","DOI":"10.1182\/blood.V108.11.2769.2769"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0029-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-007-0029-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0029-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T23:32:33Z","timestamp":1587943953000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-007-0029-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["29"],"URL":"https:\/\/doi.org\/10.1007\/s11899-007-0029-8","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}